BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 38648728)

  • 1. Research strategies of small molecules as chemotherapeutics to overcome multiple myeloma resistance.
    Yang J; Yu YC; Wang ZX; Li QQ; Ding N; Leng XJ; Cai J; Zhang MY; Wang JJ; Zhou Y; Wei TH; Xue X; Dai WC; Sun SL; Yang Y; Li NG; Shi ZH
    Eur J Med Chem; 2024 May; 271():116435. PubMed ID: 38648728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emerging Therapeutic Strategies for Overcoming Proteasome Inhibitor Resistance.
    Dolloff NG
    Adv Cancer Res; 2015; 127():191-226. PubMed ID: 26093901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proteasome inhibitors in treatment of multiple myeloma].
    Kubiczková L; Matějíková J; Sedlaříková L; Kryukov F; Hájek R; Sevčíková S
    Klin Onkol; 2013; 26(1):11-8. PubMed ID: 23528167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteasome inhibitors for multiple myeloma.
    Okazuka K; Ishida T
    Jpn J Clin Oncol; 2018 Sep; 48(9):785-793. PubMed ID: 30102324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Research Progress on Mechanism of Bortezomib Resistance in Multiple Myeloma].
    Wang YR; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1584-1587. PubMed ID: 37846721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
    Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
    Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to the Proteasome Inhibitors: Lessons from Multiple Myeloma and Mantle Cell Lymphoma.
    Gonzalez-Santamarta M; Quinet G; Reyes-Garau D; Sola B; Roué G; Rodriguez MS
    Adv Exp Med Biol; 2020; 1233():153-174. PubMed ID: 32274756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
    Driscoll JJ; Brailey M
    Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyphyllin VII, a novel moesin inhibitor, suppresses cell growth and overcomes bortezomib resistance in multiple myeloma.
    Wang H; Xiao X; Li Z; Luo S; Hu L; Yi H; Xiang R; Zhu Y; Wang Y; Zhu L; Xiao L; Dai C; Aziz A; Yuan L; Cui Y; Li R; Gong F; Liu X; Liang L; Peng H; Zhou H; Liu J
    Cancer Lett; 2022 Jul; 537():215647. PubMed ID: 35306105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New orally active proteasome inhibitors in multiple myeloma.
    Allegra A; Alonci A; Gerace D; Russo S; Innao V; Calabrò L; Musolino C
    Leuk Res; 2014 Jan; 38(1):1-9. PubMed ID: 24239172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
    Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
    Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
    Abramson HN
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):611-627. PubMed ID: 30001985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene Networks Constructed Through Simulated Treatment Learning can Predict Proteasome Inhibitor Benefit in Multiple Myeloma.
    Ubels J; Sonneveld P; van Vliet MH; de Ridder J
    Clin Cancer Res; 2020 Nov; 26(22):5952-5961. PubMed ID: 32913136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking Convergence and Cure with New Myeloma Therapies.
    Choudhry P; Galligan D; Wiita AP
    Trends Cancer; 2018 Aug; 4(8):567-582. PubMed ID: 30064664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment.
    Chroma K; Skrott Z; Gursky J; Bacovsky J; Moudry P; Buchtova T; Mistrik M; Bartek J
    Cell Death Dis; 2022 Mar; 13(3):203. PubMed ID: 35246527
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
    Gu C; Wang Y; Zhang L; Qiao L; Sun S; Shao M; Tang X; Ding P; Tang C; Cao Y; Zhou Y; Guo M; Wei R; Li N; Xiao Y; Duan J; Yang Y
    J Exp Clin Cancer Res; 2022 Jan; 41(1):11. PubMed ID: 34991674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in research on potential inhibitors of multiple myeloma.
    Tang G; Huang S; Luo J; Wu Y; Zheng S; Tong R; Zhong L; Shi J
    Eur J Med Chem; 2023 Dec; 262():115875. PubMed ID: 37879169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets.
    Hideshima T; Mitsiades C; Tonon G; Richardson PG; Anderson KC
    Nat Rev Cancer; 2007 Aug; 7(8):585-98. PubMed ID: 17646864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.